-

04:23:12 AM

CLLS Stock News

CLLS - Cellectis

08/04/22 4:30 PM

Nasdaq : CLLS

earnings

Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

IND clearance received from FDA for UCART20x22 for the treatment of Non-Hodgkin Lymphoma Cellectis unveiled novel immune-evasive universal allogeneic CAR T-cell in Nature Communications; awarded oral presentation at ASGCT in May Mr. Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D. appointed

RHEA-AI

neutral

08/01/22 4:30 PM

Nasdaq : CLLS

Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies

UCART20x22 is Cellectis’ first allogeneic dual CAR T, targeting CD20 and CD22 simultaneously UCART20x22 is Cellectis’ first product candidate fully designed, developed and manufactured in-house Phase 1/2a clinical trial NatHaLi-01 expected to begin in second half of the year NEW YORK, Aug. 01,

RHEA-AI

neutral

07/28/22 4:30 PM

Nasdaq : CLLS

conferencesearnings

Cellectis to Report Second Quarter 2022 Financial Results

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the second

RHEA-AI

neutral

06/30/22 5:19 AM

Nasdaq : CLLS

Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence

Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today publishes research data on its novel

RHEA-AI

neutral

06/28/22 4:36 PM

Nasdaq : CLLS

management

Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that during the annual shareholders

RHEA-AI

neutral

06/28/22 4:08 PM

Nasdaq : CLLS

Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022

Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June 28, 2022 at its head office in Paris, France. At the meeting, during which 67.23% of voting rights were exercised, Resolutions 1 through 23 and

RHEA-AI

neutral

06/08/22 4:30 PM

Nasdaq : CLLS

Monthly information on share capital and company voting rights

Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the capital Total number of voting rights 05/31/2022 45,510,810 51,103,546 About

RHEA-AI

neutral

05/23/22 4:35 PM

Nasdaq : CLLS

Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022

Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its combined general meeting on June 28,

RHEA-AI

neutral

05/16/22 8:15 AM

Nasdaq : CLLS

Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today will present its first research data on the

RHEA-AI

neutral

05/12/22 4:31 PM

Nasdaq : CLLS

earnings

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022

◦ UCART20x22 preclinical data presented at AACR demonstrated PoC with robust in vitro and in vivo anti-tumor activity ◦ Published two articles in Nature Communications providing preclinical validation for the evaluation of UCART123 to treat AML and BPDCN ◦ Received a $20 million convertible

RHEA-AI

neutral

1 2 3 4 5 6 7 Next